Chlamydia vaccine shows promise in early trials

The first ever early clinical trial for a chlamydia vaccine has shown it to be safe and effective at provoking an immune response.

The first ever early clinical trial for a chlamydia vaccine has shown it to be safe and effective at provoking an immune response.

The latest findings, from a randomised controlled trial of 35 healthy women led by Imperial College London and the Statens Serum Institut in Copenhagen, demonstrate promising early signs of what could be an effective vaccine against genital chlamydia.

The infection is the most common bacterial sexually transmitted infection (STI) worldwide and it can lead to infertility.

The researchers highlight that the work is ‘important first step’ but add that further trials are now needed to determine whether the immune response provoked by the vaccine will effectively protect against chlamydia infection.

Chlamydia trachomatis is one of the most prevalent bacterial STIs, representing a major global health burden, with 131 million new cases occurring each year. However, as many as three out of four infections are symptomless, so the number of cases is likely to be underestimated.

National screening programmes and antibiotic treatment have failed to reduce infection rates, and the highest number of new cases are found in teenagers and young adults.

While infection can often be treated with antibiotics, complications can include inflammation, infertility, ectopic pregnancy, arthritis and even an increased susceptibility to other STIs, including HIV.

In the latest trial, researchers compared two different formulations of the new vaccine to examine which would perform better. The 35 women not infected with chlamydia included in the trial were randomly assigned to three different groups: 15 participants received the vaccine with liposomes, 15 received the vaccine with aluminium hydroxide, and five received saline solution (placebo).

In total, participants received five vaccinations with three intramuscular injections in the arm over several months, followed by two intranasal boosts.

Both formulations of the vaccine provoked an immune response in 100% of participants, whereas no participants in the placebo group achieved an immune response.

Although both formulations of the vaccine were found to provoke an immune response, the added liposomes consistently performed better and produced more antibodies, so the authors suggest this formulation should be pursued for further clinical development.

The full findings are published in the journal The Lancet Infectious Diseases. The group is now planning phase 2 trials.